Findings link FSCN1 to the AKT/mTOR/SREBP1/(FASN/SCD1) lipogenic axis and the p38 MAPK/PPARα/ACOX1 peroxisomal FAO pathway, implicating FSCN1 in lipid metabolic regulation and CRC progression, while suggesting a putative functional regulatory axis and a promising candidate therapeutic target for CRC.
Abstract
Background: Fascin actin-bundling protein 1 (FSCN1) modulates the expression of key lipogenic enzymes fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD1) in colorectal cancer (CRC), but the underlying mechanisms remain elusive. Methods: Bioinformatics analyses were performed to evaluate FSCN1 expression and its prognostic value in CRC. Intracellular lipid levels following FSCN1 knockdown were assessed by Nile Red/DAPI co-staining and triglyceride quantification, and further validated by Oil Red O staining of xenograft tumors. Expression levels of key metabolic enzymes were measured by qRT-PCR and Western blotting. RNA sequencing identified FSCN1-associated pathways, which were functionally investigated using pharmacological inhibitors. Results: FSCN1 was significantly upregulated in CRC (p < 0.001; AUC = 0.796) and was correlated with poorer overall survival (p = 0.018). FSCN1 depletion reduced intracellular lipid accumulation, accompanied by downregulation of lipogenic mediators—sterol regulatory element-binding transcription factor 1 (SREBF1; protein product: SREBP1), FASN, and SCD1—and upregulation of peroxisomal fatty acid oxidation (FAO)-related factors—peroxisome proliferator-activated receptor alpha (PPARA; protein product: PPARα) and acyl-CoA oxidase 1 (ACOX1). Mechanistically, FSCN1 was associated with activation of the protein kinase B/mammalian target of rapamycin (AKT/mTOR) and p38 mitogen-activated protein kinase (p38 MAPK) pathways; pharmacological inhibition with LY294002 or SB203580 phenocopied the lipid-lowering effects of FSCN1 knockdown. Conclusion: Collectively, these findings link FSCN1 to the AKT/mTOR/SREBP1/(FASN/SCD1) lipogenic axis and the p38 MAPK/PPARα/ACOX1 peroxisomal FAO pathway, implicating FSCN1 in lipid metabolic regulation and CRC progression, while suggesting a putative functional regulatory axis and a promising candidate therapeutic target for CRC.
TGFBR3 interacts with FATP2 and is associated with the regulation of migration and invasion in lung cancer cells, potentially involving the FATP2-ACSL1 axis.
Tian Luo, Yuanyuan Wu, Nuoya Ma et al.· Frontiers in Oncology· 0 citations
PPT1 overexpression promotes GC progression by activating the ERK signaling pathway and thereby modulating lipid metabolism, suggesting its potential as a novel prognostic biomarker and a therapeutic target for GC.
Bingyi Huang, Yu-Jie Gao, Jing-Yi Xie et al.· Nan fang yi ke da xue xue ba...· 0 citations
Hepatocellular carcinoma (HCC) is a common malignancy characterised by molecular heterogeneity and poor prognosis. The purpose of this study was to determine differences in the expression of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Fatty Acid Synthase (FASN), FKBP12-rapamycin-associated protein (FRAP...
It is demonstrated that PSMD11 was markedly upregulated in HCC tissues and correlated with poor patient prognosis, and a PSMD11–PSMD14–SREBP1/2-PPAR-γ–CPT1A regulatory axis that orchestrates metabolic reprogramming in HCC is uncovered.
Zhi-Hong Huang, Can-Xue Zhang, Chi Zhang et al.· Cell Death & Disease· 0 citations
Background Fatty acid binding protein 5 (FABP5) contributes to lipid metabolism and inflammation, but, its immunoregulatory role in hepatocellular carcinoma (HCC) is unclear. Considering the strong metabolic–immune interplay in HCC, elucidating how FABP5 shapes the tumor immune microenvironment may uncover new therapeu...
Rui An, Shi-Bing Hou, M. Hong et al.· PLoS ONE· 0 citations
Experimental data indicated that P4HA3 facilitated GC cell proliferation, migration and invasion, and enhanced glycolytic activity and increased the expression of key glycolysis-related proteins, suggesting that P4HA3 may induce a broader metabolic activation rather than an exclusively glycolytic shift.
Tao Wang, Xiao Xu, C. Jin et al.· Pakistan Journal of Pharmace...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.